



Nasal Swab Sampling for SARS-CoV-2: a Convenient Alternative in Times of Nasopharyngeal Swab Shortage

Hélène Péré, a,b,c Isabelle Podglajen,c,d Maxime Wack,e,f Edouard Flamarion,g Tristan Mirault,b,h Guillaume Goudot,b,h Caroline Hauw-Berlemont, Laetitia Le,j,k Eric Caudron,j,k Sophie Carrabin,g Julien Rodary,a Tatiana Ribeyre,a Laurent Bélec,a,c,d David Veyera,c,l

^aLaboratoire de Virologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France

KEYWORDS COVID-19, nasal swab, nasopharyngeal swab, RT-PCR, SARS-CoV-2, molecular diagnosis

asopharyngeal swab is the reference sampling method to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as recommended by the World Health Organization (WHO) (1). However, nasal specimens may have a slightly lower sensitivity than nasopharyngeal specimens (2, 3). We herein validated an alternative procedure to collect nasal secretions with a swab routinely used in medical bacteriology for which there is no risk of supply disruption in order to perform the molecular diagnosis of SARS-CoV-2 infection.

Patients who were suspected of having coronavirus disease 2019 (COVID-19) attending the Hôpital Européen Georges Pompidou, Paris, France, were for their own care according to medical decision prospectively included and subjected to SARS-CoV-2 molecular testing using nasopharyngeal swab (Xpert nasopharyngeal sample collection kit; Cepheid, Sunnyvale, CA, USA) and nasal swab (Copan Transystem; Copan, Brescia, Italy).

Nasal and nasopharyngeal swabs were inserted in the nostril until they hit an obstacle (the inferior concha and the back of the nasopharyngeal cavity, respectively), rotated five times, and removed. The test was conducted in only one nostril per patient. After sampling, the nasopharyngeal swab was inserted into a vial containing 3 ml of virus transport medium (Xpert viral transport medium; Cepheid), and the nasal swab was placed in a 15-ml tube containing 3 ml of saline solution (0.9% NaCl). SARS CoV-2 was detected using Allplex 2019-nCoV assay (Seegene, Seoul, Korea).

A total of 44 patients were prospectively included up to the end of March 2020. Their median age was 63.0 years, ranging from 18 to 94 years. There were 23 (52.3%) male and 21 female patients. A total of 37 (84.1%) patients showed laboratory-confirmed SARS-CoV-2 infection using nasopharyngeal swab, with 7 patients giving negative results (15.9%) (Table 1).

Citation Péré H, Podglajen I, Wack M, Flamarion E, Mirault T, Goudot G, Hauw-Berlemont C, Le L, Caudron E, Carrabin S, Rodary J, Ribeyre T, Bélec L, Veyer D. 2020. Nasal swab sampling for SARS-CoV-2: a convenient alternative in times of nasopharyngeal swab shortage. J Clin Microbiol 58:e00721-20. https://doi.org/10 .1128/JCM.00721-20.

Editor Alexander J. McAdam, Boston Children's Hospital

Copyright © 2020 Péré et al. This is an openaccess article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to David Veyer, david.veyer@aphp.fr.

Accepted manuscript posted online 15 April 2020

Published 26 May 2020

bINSERM U970, PARCC, Hôpital Européen Georges Pompidou, Faculté de Médecine, Université de Paris, Paris, France

c Service de Microbiologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France

^dFaculté de Médecine Paris Descartes, Sorbonne Paris Cité, Université de Paris, Paris, France

eDépartement d'Informatique Médicale, Biostatistiques et Santé Publique, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Praris, France

^fCentre de Recherche des Cordeliers, INSERM, UMRS 1138, Université de Paris, Paris, France

⁹Département de Médecine Interne, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France

^hDépartment de Médecine Vasculaire, HYPERVASC, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France

Service de Médecine Intensive-Réanimation, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France

¹Laboratoire de Chimie Analytique Pharmaceutique, EA7357, Université Paris Sud-Paris-Saclay, Châtenay-Malabry, France

^kDépartment de Pharmacie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France

^{&#}x27;Unité de Génomique Fonctionnelle des Tumeurs Solides, Centre de Recherche des Cordeliers, INSERM, Université de Paris, Paris, France

Letter to the Editor Journal of Clinical Microbiology

TABLE 1 Comparison of nasopharyngeal versus nasal sampling for SARS-CoV-2 detection by molecular biology

Nasopharyngeal sample/nasal	
sample results	No. of samples (%)
Concordant results	
Positive/positive	33 (75.0)
Negative/negative	7 (15.9)
Discordant results	
Positive/negative ^a	4 (9.1)
Total	44 (100.0)

^aOf the four samples with discordant results, two samples had very low viral loads (C_T of 38 on the N gene).

Out of 37 patients that were positive for SARS-CoV-2 by nasopharyngeal swab testing, 33 also tested positive by nasal sampling. All SARS-CoV-2-negative patients with nasopharyngeal swabs (n = 7) gave negative test results using nasal swabs (Table 1).

By reference to nasopharyngeal sampling, the detection of SARS-CoV-2 by nasal sampling provided 7 (15.9%) true SARS-CoV-2-negative specimens, 4 (9.1%) false-negative specimens, and 33 (75.0%) true SARS-CoV-2-positive specimens. Thus, the sensitivity of SARS-CoV-2 RNA detection by multiplex real-time PCR from nasal secretions was 89.2% (95% confidence interval [95% CI], 75.3 to 95.7), and its specificity was 100.0% (95% CI, 94.6 to 100.0). The κ index was 0.72, indicating substantial concordance between nasal and nasopharyngeal swabbing to detect SARS-CoV-2 according to Landlis and Koch rank. The Youden J index was calculated at 89.2%, demonstrating good efficiency to detect SARS-CoV-2 RNA.

Threshold cycle (C_7) (mean \pm standard deviation [SD]) values for E (envelope), RdRP (RNA-dependent RNA polymerase) and N (nucleocapsid) genes by nasopharyngeal (23.9 \pm 4.9 for E, 26.3 \pm 5.5 for E, and 28.9 \pm 6.1 for E0) and nasal (22.3 \pm 5.2 for E7, 24.6 \pm 5.9 for E8, and 27.9 \pm 6.1 for E9) swab testing were similar. Differences in E9 values for the E7, E8, and E9 genes were not statistically significant (E9 0.56, 0.84, and 0.57, respectively).

We herein report that the molecular detection of SARS-CoV-2 using nasal swab specimens was nearly equivalent to the detection using nasopharyngeal swab considered the gold standard. SARS-CoV-2 detection from nasal samples showed high sensitivity and specificity. Agreement and accuracy of test results using nasal sampling by reference to gold standard nasopharyngeal sampling were estimated as substantial and good, respectively. Taken together, these observations demonstrate that nasal sampling could be used to screen SARS-CoV-2 in times of nasopharyngeal swab shortage.

ACKNOWLEDGMENTS

We thank the patients and the nurses and clinical staff who are providing care for the patients.

REFERENCES

- World Health Organization. 19 March 2020. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. Interim guidance. WHO/COVID-19/laboratory/2020.5. World Health Organization, Geneva, Switzerland. https://www.who.int/publications-detail/laboratory -testing-for-2019-novel-coronavirus-in-suspected-human-cases -20200117. Accessed 27 March 2020.
- 2. Lambert SB, Whiley DM, O'Neill NT, Andrews EC, Canavan FM, Bletchly C, Siebert DJ, Sloots TP, Nissen MD. 2008. Comparing nose-throat swabs and
- nasopharyngeal aspirates collected from children with symptoms for respiratory virus identification using real-time polymerase chain reaction. Pediatrics 122:e615–e620. https://doi.org/10.1542/peds.2008-0691.
- Meerhoff TJ, Houben ML, Coenjaerts FE, Kimpen JL, Hofland RW, Schellevis F, Bont LJ. 2010. Detection of multiple respiratory pathogens during primary respiratory infection: nasal swab *versus* nasopharyngeal aspirate using real-time polymerase chain reaction. Eur J Clin Microbiol Infect Dis 29:365–371. https://doi.org/10.1007/s10096-009-0865-7.